JP2013512866A5 - - Google Patents

Download PDF

Info

Publication number
JP2013512866A5
JP2013512866A5 JP2012541362A JP2012541362A JP2013512866A5 JP 2013512866 A5 JP2013512866 A5 JP 2013512866A5 JP 2012541362 A JP2012541362 A JP 2012541362A JP 2012541362 A JP2012541362 A JP 2012541362A JP 2013512866 A5 JP2013512866 A5 JP 2013512866A5
Authority
JP
Japan
Prior art keywords
protein
ferlin
epitope
antigenic determinant
plasmodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012541362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013512866A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/007399 external-priority patent/WO2011066995A1/en
Publication of JP2013512866A publication Critical patent/JP2013512866A/ja
Publication of JP2013512866A5 publication Critical patent/JP2013512866A5/ja
Pending legal-status Critical Current

Links

JP2012541362A 2009-12-05 2010-12-06 アピコンプレクサFerlin、Ferlin様タンパク質、及び他のC2ドメイン含有タンパク質に基づくマラリアワクチン Pending JP2013512866A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26702609P 2009-12-05 2009-12-05
US61/267,026 2009-12-05
PCT/EP2010/007399 WO2011066995A1 (en) 2009-12-05 2010-12-06 Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins

Publications (2)

Publication Number Publication Date
JP2013512866A JP2013512866A (ja) 2013-04-18
JP2013512866A5 true JP2013512866A5 (enExample) 2017-01-26

Family

ID=43499977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012541362A Pending JP2013512866A (ja) 2009-12-05 2010-12-06 アピコンプレクサFerlin、Ferlin様タンパク質、及び他のC2ドメイン含有タンパク質に基づくマラリアワクチン

Country Status (8)

Country Link
US (1) US8968750B2 (enExample)
EP (1) EP2507259B1 (enExample)
JP (1) JP2013512866A (enExample)
CN (1) CN102781958B (enExample)
BR (1) BR112012013581A8 (enExample)
CA (1) CA2783107C (enExample)
MX (1) MX2012006458A (enExample)
WO (1) WO2011066995A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2648744B1 (en) 2010-12-06 2020-06-03 MalVa GmbH Malaria vaccines based on pre-erythrocytic antigens from p. falciparum
DK2941269T3 (da) * 2013-01-07 2021-01-11 Mucosal Vaccine Tech Llc Terapeutiske vacciner til behandling af herpes simplex-virus type 2-infektioner
CR20170060A (es) 2014-08-19 2017-04-18 Merck Sharp & Dohme Anticuerpos anti tigit
JP6976241B2 (ja) * 2015-08-14 2021-12-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗tigit抗体
JP2017210441A (ja) * 2016-05-26 2017-11-30 国立大学法人大阪大学 マラリアワクチン

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518528A (en) * 1983-05-19 1985-05-21 Rasnick David W α Amino fluoro ketones
US5198334A (en) * 1989-07-21 1993-03-30 Terumo Corporation Protection of natural killer cell cytolytic activity in peripheral blood mononuclear cells
GB9406492D0 (en) * 1994-03-31 1994-05-25 Isis Innovation Malaria peptides
JP2001509813A (ja) * 1997-01-21 2001-07-24 ニューヨーク ユニヴァーシティ 抗マラリアワクチン用ユニバーサルt細胞エピトープ
US20030077653A1 (en) * 2000-04-20 2003-04-24 The University Of Georgia Research Foundation, Inc. Method for the identification of active site protease inactivators
US7811575B2 (en) * 2001-04-10 2010-10-12 Agensys, Inc. Nucleic acids and corresponding proteins entitled 158P3D2 useful in treatment and detection of cancer
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
CA2409897A1 (en) * 2002-10-25 2004-04-25 Institut Pasteur Plasmodium falciparum virulence factor var o
US7198791B2 (en) * 2003-03-03 2007-04-03 Pluschke, Gerd Et Al. Compositions and methods for the generation of protective immune responses against malaria
WO2005018665A1 (en) * 2003-08-26 2005-03-03 The Council Of The Queensland Institute Of Medical Research Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens including plasmodium spp
WO2005063804A1 (en) * 2003-12-30 2005-07-14 Københavns Universitet Panum Compounds useful in the diagnosis and treatment of malaria
EP1930017B1 (en) * 2005-09-29 2012-05-23 Maruha Nichiro Seafoods, Inc. Composition effective for prevention and treatment of adult disease
GB0601059D0 (en) * 2006-01-19 2006-03-01 Univ Durham Target
WO2009082440A2 (en) * 2007-12-18 2009-07-02 Vaxinnate Corporation Compositions of toll-like receptor agonists and malaria antigens and methods of use
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US20110165649A1 (en) * 2010-01-06 2011-07-07 Brett Tyler Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts
EP2648744B1 (en) * 2010-12-06 2020-06-03 MalVa GmbH Malaria vaccines based on pre-erythrocytic antigens from p. falciparum

Similar Documents

Publication Publication Date Title
Kaba et al. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria
Mettens et al. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS, S vaccine antigen
Nardin et al. Plasmodium falciparum polyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein
JP2012501959A5 (enExample)
JP2023513720A5 (enExample)
JP7261013B2 (ja) マラリアワクチンにおいて使用するための新規抗原
CN1241639C (zh) 抵抗疟疾的疫苗组合物
JP2013527760A5 (enExample)
JP2016146837A5 (enExample)
JP2021519599A (ja) 抗原性ospaポリペプチド
RU2012114483A (ru) Вирусоподобные частицы, содержащие белки-мишени, слитые с белками оболочки растительных вирусов
JP2014507146A5 (enExample)
Yoshida et al. A baculovirus dual expression system-based malaria vaccine induces strong protection against Plasmodium berghei sporozoite challenge in mice
Teixeira et al. Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents
TW201803907A (zh) 作為抗瘧疾疫苗之生物融合蛋白
Li et al. Surface display of classical swine fever virus E2 glycoprotein on gram-positive enhancer matrix (GEM) particles via the SpyTag/SpyCatcher system
RU2007109608A (ru) Вакцины, содержащие антиген plasmodium
Roggero et al. The synthetic, oxidized C‐terminal fragment of the Plasmodium. berghei circumsporozoite protein elicits a high protective response
JP2010535504A5 (enExample)
EA201171347A1 (ru) Комбинированная вакцина против кори и малярии
EP2915544B1 (en) Chimeric vaccine antigens against hepatitis c virus
CN113476600B (zh) Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物
US9505812B2 (en) Plasmodium falciparum antigens
JP2018070571A (ja) 免疫誘導剤
Reeder et al. Strategic variants of CSP delivered as SynDNA vaccines demonstrate heterogeneity of immunogenicity and protection from Plasmodium infection in a murine model